{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:41:04Z","timestamp":1789177264341,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T00:00:00Z","timestamp":1255564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T00:00:00Z","timestamp":1255564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s10637-009-9344-3","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T14:31:42Z","timestamp":1255530702000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase I trial of vinflunine and pemetrexed in refractory solid tumors"],"prefix":"10.1007","volume":"29","author":[{"given":"Hanna K.","family":"Sanoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Walko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Buie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Keung","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Stinchcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Claire","family":"Dees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,15]]},"reference":[{"issue":"6","key":"9344_CR1","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-07-2219","volume":"14","author":"J Bennouna","year":"2008","unstructured":"Bennouna J, Delord JP, Campone M, Nguyen L (2008) Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 14(6):1625\u20131632","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9344_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s002800050764","volume":"41","author":"A Kruczynski","year":"1998","unstructured":"Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT (1998) Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 41(6):437\u2013447","journal-title":"Cancer Chemother Pharmacol."},{"issue":"9","key":"9344_CR3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/sj.bjc.6603347","volume":"95","author":"M Campone","year":"2006","unstructured":"Campone M, Cortes-Funes H, Vorobiof D et al (2006) Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline\/taxane-based chemotherapy. Br J Cancer 95(9):1161\u20131166","journal-title":"Br J Cancer"},{"issue":"10","key":"9344_CR4","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/sj.bjc.6603118","volume":"94","author":"S Culine","year":"2006","unstructured":"Culine S, Theodore C, De Santis M et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94(10):1395\u20131401","journal-title":"Br J Cancer"},{"issue":"30","key":"9344_CR5","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1200\/JCO.2007.12.5641","volume":"25","author":"DC Talbot","year":"2007","unstructured":"Talbot DC, Margery J, Dabouis G et al (2007) Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 25(30):4751\u20134756","journal-title":"J Clin Oncol"},{"key":"9344_CR6","doi-asserted-by":"crossref","unstructured":"Krzakowski M, Douillard J, Ramlau R, et al. (2007) Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. J Clin Oncol. 25(18\u00a0S):(abstr 7511).","DOI":"10.1200\/jco.2007.25.18_suppl.7511"},{"issue":"4","key":"9344_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/annonc\/mdg174","volume":"14","author":"J Bennouna","year":"2003","unstructured":"Bennouna J, Fumoleau P, Armand JP et al (Apr 2003) Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3\u00a0weeks in patients with advanced solid tumours. Ann Oncol. 14(4):630\u2013637","journal-title":"Ann Oncol."},{"issue":"(12 Pt 2)","key":"9344_CR8","doi-asserted-by":"publisher","first-page":"4276s","DOI":"10.1158\/1078-0432.CCR-040010","volume":"10","author":"AA Adjei","year":"2004","unstructured":"Adjei AA (2004) Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10((12 Pt 2)):4276s\u20134280s","journal-title":"Clin Cancer Res"},{"issue":"9","key":"9344_CR9","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589\u20131597","journal-title":"J Clin Oncol"},{"issue":"3","key":"9344_CR10","first-page":"1016","volume":"6","author":"BA Teicher","year":"2000","unstructured":"Teicher BA, Chen V, Shih C et al (Mar 2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res. 6(3):1016\u20131023","journal-title":"Clin Cancer Res."},{"issue":"3","key":"9344_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","volume":"10","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bertino JS, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10(3):187\u2013216","journal-title":"Pharmacogenetics"},{"issue":"1\u20132","key":"9344_CR12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.chroma.2003.12.039","volume":"1031","author":"H Kanazawa","year":"2004","unstructured":"Kanazawa H, Okada A, Igarashi E et al (2004) Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry. J Chromatogr A 1031(1\u20132):213\u2013218","journal-title":"J Chromatogr A"},{"key":"9344_CR13","doi-asserted-by":"crossref","unstructured":"Fumoleau P, Cortes-Funes H, Taleb AB, et al. (2009) Phase 2 Study of Single-Agent IV Vinflunine as Third-Line Treatment of Metastatic Breast Cancer After Failure of Anthracycline-\/Taxane-Based Chemotherapy. Am J Clin Oncol.","DOI":"10.1097\/COC.0b013e31818f2d2f"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9344-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9344-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:47:06Z","timestamp":1678510026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9344-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,15]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["9344"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9344-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,15]]},"assertion":[{"value":"22 September 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}